
# TESTIMONIALS

"I am very grateful to the Israel Cancer Research Fund for supporting the work of cancer researchers in Israel, including my own research." – Nobel Prize recipient Prof. Avram Hershko

"ICRF seeded my scientific trip... My research is a product of ICRF."

- Nobel Prize recipient Prof. Aaron Ciechanover



Dr. Hershko and Dr. Ciechanover were awarded the Nobel Prize in Chemistry for their discovery of the ubiquitin system. This discovery laid the groundwork for the drug Velcade<sup>o</sup>, which is used to treat multiple myeloma.



### **ICRF Chapters**

**International Executive and New York Regional Offices** 52 Vanderbilt Ave, Suite 1510 New York, NY 10017-3834 Tel. 212-969-9800 Email info@icrfonline.org

### Chicago

1 Northfield Plaza, Suite 235 Northfield, IL 60093 Tel. 847-441-1824 Email chicago@icrfonline.org

### **Connecticut Area**

7 Lumanor Drive, Stamford, CT 06903 Tel. 203-321-1006 Email ct@icrfonline.org

### Los Angeles

1920 Hillhurst Ave, #1109, Los Angeles, CA 90027 Tel. 818-986-2100 Email la@icrfonline.org

### Montreal

1310 Greene Avenue, Suite 710 Westmount, QC H3Z 2B2 Tel. 514-481-2723 Email info@icrfmontreal.org

#### Toronto

1881 Yonge Street, Box 29, Suite 616 Toronto, ON M4S 3C4 Tel. 416-487-5246 Email research@icrf.ca

### Israel

3 Hata'asiyah, POB 10050, Tel Aviv 67139 03 Tel. 011-972-54-678-7800 Email mor@icrf.org.il

Visit our website and donate online: **www.icrfonline.org** 

Follow us on social media: @ICRFONLINE THE ANSWER TO CANCER IS RESEARCH

Partner with ICRF and support Israel's scientists in groundbreaking cancer research for the benefit of all humankind.

Israel

Fund

Cancer Research

"I have a naive faith that the answer to cancer will come from Israel, because Israel has given to humanity a concept of celebrating life." - Elie Wiesel

# Our Mission

ICRF's mission is to support the best and brightest scientists conducting groundbreaking cancer research in Israel.

## Our Vision

ICRF's vision is to eliminate suffering caused by cancer.

## Our History

ICRF is a nonprofit organization founded in 1975 by a group of American and Canadian physicians, scientists and philanthropists who recognized the extraordinary accomplishments and unique global impact of science in Israel. They envisioned Israel as a world-leader in cancer research. Now, hundreds of Israeli scientists across all fields of cancer are inspired by North American funding to conduct their research in world-class Israeli biomedical institutions.





# MAJOR ACCOMPLISHMENTS

- Instrumental in the development of breakthrough FDA-approved drugs: Gleevec<sup>®</sup> (blood cancers), Doxil<sup>®</sup> (solid tumors), and Velcade<sup>®</sup> (blood cancers)
- Major breakthroughs in cancer treatment:
  - Nano-medicine
  - O Immunotherapy
  - O Stem cell research
  - O Targeted therapy
- ICRF-funded researchers awarded Nobel Prize in Chemistry

# **ICRF BY THE NUMBERS**

# \$72M+ allocated to date 2,500 grants awarded

Currently funding more than **70 research projects**, making ICRF the largest non-governmental funder of cancer research in Israel.

# WHY SUPPORT ICRF?

# We are at the forefront of cancer discoveries

We have provided the funding for hundreds of Israeli scientists who have conducted groundbreaking research.

### We select the best

Our grant-making process is overseen by our volunteer Scientific Review Panel, a group of leading physicians and scientists from major research institutions throughout North America. These prominent professionals collectively donate thousands of hours to review each grant application in an intensive peer-review process.

### We are efficient with your gift

Donations to ICRF directly support the Israeli scientists and their labs, not bricks and mortar.

### We are committed to collaboration

ICRF collaborates with some of the best cancer hospitals and organizations in North America. For example, the ICRF-City of Hope (COH) Jacki and Bruce Barron Cancer Research Scholars' Program fosters innovative collaborative research and promotes the exchange of ideas between exceptional researchers from COH and Israel.

# **MAKE AN IMPACT**

### Your contribution can help save lives!

Join us and support life-saving cancer research by funding an ICRF Grant. A designated grant can bear your name and you will receive information from the researcher. At every giving level, you have the opportunity to support life-changing discoveries in cancer research.

### Named Scientific Grant Opportunities:

### **Professorship Grants**

(\$550,000 over a 5-year period) Awarded to full-time, senior scientists with established laboratories, who have made outstanding contributions to cancer research.

### **Project Grants**

(\$198,000 over a 3-year period) Awarded to established investigators working on specific cancer research projects.

### **Clinical Research Career Development Awards**

(\$148,500 over a 3-year period) Awarded to promising medical or pediatric oncologists to conduct clinical research projects and obtain additional training to become leaders in the field.

#### **Research Career Development Awards**

(\$148,500 over a 3-year period) Awarded to promising investigators who have recently established their own laboratories, and are on their way to becoming outstanding independent investigators.

#### **Postdoctoral Fellowships**

(\$99,000 over a 3-year period) Awarded to new MDs and PhDs who will apprentice in the laboratories of senior investigators.

### Special Grants:

#### **Acceleration Grants**

(\$154,000 over a 3-year period) Awarded to investigators proposing highly innovative approaches that promise to pioneer new ways of thinking about cancer biology and therapeutics.

#### **Collaborative Funding Awards**

(\$495,000 over a 3-year period) Awarded to cancer research projects conducted collaboratively with scientists at a North American research institution and investigators in Israel.

### **Special Funding Initiatives**

(Minimum of \$550,000 over a 3-year period)

Awarded to investigators conducting cancer research projects in a particular discipline or cancer type that is initiated directly by a donor and approved by ICRF's International Scientific Council.